Tranexamic Acid in Dacryocystorhinostomy (TA-DCR)

HaEmek Medical Center, Israel

Status: Unknown

Conditions: Nasolacrimal Tract Obstruction

Treatments: Drug: saline solution; Drug: Tranexamic acid

Study type: Interventional

Funder types: Other

Identifiers

NCT01221909

EMC-DCR-TA

Details and patient eligibility

About

Single dose tranexamic acid (TA) before dacryocystorhinostomy (DCR) operation: a prospective, double blind, placebo controlled study.

The study hypothesis: TA in DCR might reduce the intraoperative and postoperative bleeding in DCR surgery, and might reduce the duration of the surgery.

Enrollment: 80 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• obstruction of nasolacrimal pathway
• eligible for DCR surgery
• 18 years of age or older

Exclusion criteria

• warfarin treatment
• renal insufficiency
• pregnancy
• mental retardation
• tendency to bleed
• thromboembolic disease
• thrombophilia

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Single Group Assignment

Masking: Double Blind

---

80 participants in 2 patient groups, including a placebo group

Tranexamic acid single dose of 500mg

Experimental group

Treatment:

Drug: Tranexamic acid

Saline

Placebo Comparator group

Treatment:

Drug: saline solution